Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Senti Biosciences Inc (SNTI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/26/2025: SNTI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -70.13% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 45.89M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 39359 | Beta 2.75 | 52 Weeks Range 1.52 - 10.00 | Updated Date 03/30/2025 |
52 Weeks Range 1.52 - 10.00 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -15.59 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-03-21 | When - | Estimate - | Actual -0.6719 |
Profitability
Profit Margin - | Operating Margin (TTM) -18017.46% |
Management Effectiveness
Return on Assets (TTM) -33.02% | Return on Equity (TTM) -111.07% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 69878189 | Price to Sales(TTM) 55.46 |
Enterprise Value 69878189 | Price to Sales(TTM) 55.46 | ||
Enterprise Value to Revenue 134.22 | Enterprise Value to EBITDA -0.28 | Shares Outstanding 4588640 | Shares Floating 2920793 |
Shares Outstanding 4588640 | Shares Floating 2920793 | ||
Percent Insiders 21 | Percent Institutions 23.33 |
Analyst Ratings
Rating 5 | Target Price 10 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Senti Biosciences Inc
Company Overview
History and Background
Senti Biosciences, Inc. was founded in 2016 and is focused on developing gene circuits for advanced cell and gene therapies. It went public via a SPAC merger in 2022. They are creating novel technologies to program and reprogram cells with biological logic.
Core Business Areas
- Gene Circuit Platform: Develops synthetic gene circuits to program cell behavior for therapeutic applications.
- Cell and Gene Therapy: Utilizes gene circuits to engineer cell and gene therapies for cancer and other diseases.
Leadership and Structure
The company is led by a management team with expertise in biotechnology and gene therapy. The organizational structure includes research and development, clinical development, and business operations.
Top Products and Market Share
Key Offerings
- SENTI-202: An off-the-shelf CAR-NK cell therapy candidate for acute myeloid leukemia (AML) expressing a logic gate to target cells expressing both FLT3 and/or CD33. Currently in preclinical development. Competitors in AML therapy include Novartis and Bristol Myers Squibb.
- SENTI-301: An allogeneic cell therapy expressing an AND logic gate, designed to target solid tumors. In preclinical development. Competitors are companies developing CAR-T therapies for solid tumors.
Market Dynamics
Industry Overview
The cell and gene therapy market is rapidly growing, driven by technological advancements and increasing investment. There is strong demand for innovative therapies to treat cancer and genetic diseases.
Positioning
Senti Biosciences is positioned as a pioneer in gene circuit technology for cell and gene therapy. They have a unique technology platform but are in early stages of clinical development.
Total Addressable Market (TAM)
The total addressable market for cell and gene therapy is projected to reach hundreds of billions of dollars. Senti Biosciences is positioned to capture a share of this market with its innovative technology.
Upturn SWOT Analysis
Strengths
- Proprietary gene circuit technology platform
- Experienced management team
- Strong intellectual property position
- Potential to address unmet medical needs
Weaknesses
- Early stage of clinical development
- High cash burn rate
- Dependence on external funding
- Limited clinical data
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of gene circuit platform to new therapeutic areas
- Positive clinical trial results
- FDA approvals of cell and gene therapies
Threats
- Competition from established biotechnology companies
- Regulatory hurdles
- Clinical trial failures
- Economic downturn
Competitors and Market Share
Key Competitors
- BMY
- NVS
- CRSP
- EDIT
- BLUE
Competitive Landscape
Senti Biosciences competes with established biotechnology and pharmaceutical companies in the cell and gene therapy market. They have a differentiated technology platform but are in an early stage of development.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth due to the company's early stage. Growth depends on the advancement of clinical trials.
Future Projections: Future growth is dependent on successful clinical trials and potential partnerships. Analyst projections vary widely.
Recent Initiatives: Focus on advancing SENTI-202 and SENTI-301 programs, and expanding gene circuit platform.
Summary
Senti Biosciences is a high-risk, high-reward company pioneering gene circuit technology for cell and gene therapy. Its success hinges on positive clinical trial results and securing partnerships. It faces challenges due to limited clinical data, high cash burn, and competition. Investors should carefully assess these factors.
Similar Companies
- CRSP
- EDIT
- BEAM
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Industry Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. The data provided may not be complete or accurate. Investment decisions should be based on individual due diligence and risk tolerance.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Senti Biosciences Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2022-06-09 | Co-Founder, CEO & Director Dr. Timothy K. Lu M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 34 | Website https://www.sentibio.com |
Full time employees 34 | Website https://www.sentibio.com | ||
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.